Injury guide

UPDATED FEB 2026

Hair Relaxer Ovarian Cancer

Part of the Hair Relaxer Cancer investigation

The short answer

The Sister Study found hair relaxer users face a 2.19x increased risk of ovarian cancer. Ovarian cancer is often called the "silent killer" because symptoms are vague until advanced stages, making early detection difficult.

People's Justice Research TeamUpdated February 20, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

Free · Confidential · About 2 minutes · A case specialist responds within 1 business day

Your answers are never sold or shared without your consent.

The Ovarian Cancer Connection

A 2021 analysis from the NIEHS Sister Study (White et al., Carcinogenesis) found that frequent use of hair straighteners (>4 times/year) was associated with a 2.19x increased risk of ovarian cancer (HR 2.19, 95% CI: 1.12–4.27). EDCs in hair relaxers — particularly phthalates and parabens — disrupt ovarian function and promote carcinogenesis through estrogen pathway interference.

Why Ovarian Cancer Is Particularly Dangerous

Ovarian cancer is the fifth-leading cause of cancer death among women. It is often diagnosed at advanced stages because early symptoms (bloating, pelvic pain, feeling full quickly) are vague and easily attributed to other conditions. The 5-year survival rate for Stage III/IV ovarian cancer is approximately 30%.

The Talcum Powder Parallel

The hair relaxer ovarian cancer claims parallel the massive talcum powder litigation against Johnson & Johnson. In both cases: a consumer product marketed to women contained undisclosed carcinogenic substances, chronic genital-area exposure increased ovarian cancer risk, and the manufacturer failed to warn despite available evidence. J&J's $6.5 billion settlement provides a direct benchmark.

Documenting Your Ovarian Cancer Claim

Key evidence: pathology reports confirming ovarian cancer type and stage, surgical records (debulking surgery, oophorectomy), chemotherapy records, CA-125 blood test results, detailed history of hair relaxer product use and frequency.

Research & evidence

Scientific Evidence

Hair Relaxer Use and Risk of Uterine Cancer in the Black Women's Health Study

Bertrand KA, Coogan PF, Palmer JR (2023). Environmental Research

View on PubMed

Use of Straighteners and Other Hair Products and Incident Uterine Cancer

Chang CJ, O'Brien KM, Keil AP, Gaston SA, Jackson CL, Sandler DP, White AJ (2022). Journal of the National Cancer Institute

View on PubMed

Use of Hair Products in Relation to Ovarian Cancer Risk

White AJ, Sandler DP, et al. (2021). Carcinogenesis

View on PubMed

FAQ

Frequently Asked Questions

36 QUESTIONS

Chemical hair relaxers contain endocrine-disrupting chemicals (EDCs) — phthalates, parabens, formaldehyde, BPA, and cyclosiloxanes — that mimic estrogen when absorbed through the scalp. Chronic estrogen overstimulation promotes abnormal growth in hormone-sensitive tissues. The NIH Sister Study found that frequent relaxer users face a 155% increased risk of uterine cancer and a 119% increased risk of ovarian cancer.

Dive deeper

Related Guides

7 GUIDES

The full investigation

Part of the Hair Relaxer Cancer Investigation